Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Obese subjects with HFpEF (heart failure with preserved ejection fraction) | Experimental |
| |
| Active cardiac sarcoidosis | Active Comparator |
| |
| Healthy subjects | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor) | Drug | 68Ga-FAPI is a gallium-68 fibroblast activation protein inhibitor that will be injected into subjects during a PET (positron emission tomography) scan |
| Measure | Description | Time Frame |
|---|---|---|
| Myocardial 68Ga-FAPI (68Ga-Fibroblast Activation Protein Inhibitor) volume | Myocardial 68Ga-FAPI volume will be determined by a PET (positron emission tomography) scan and measured in cm3 | Baseline and 6 Months |
| Mean Standardized Uptake Value (SUVmean) and Max Standardized Uptake Value (SUVmax) | SUVmean and SUVmax will be determined by a PET (positron emission tomography) scan and measured as a dimensionless ratio | Baseline and 6 Months |
| Area of 68Ga-FAPI (68Ga-Fibroblast Activation Protein Inhibitor) uptake | Area of 68Ga-FAPI will be determined by a PET (positron emission tomography) scan and measured as a % of polar map. | Baseline and 6 Months |
| 68Ga-FAPI target-to-background ratio | 68Ga-FAPI target-to-background ratio will be determined by a PET (positron emission tomography) scan and measured as a dimensionless ratio. | Baseline and 6 Months |
Not provided
Not provided
HFpEF Group Inclusion:
HFpEF Group Exclusion:
Cardiac Sarcoid Group Inclusion:
Cardiac Sarcoid Group Exclusion:
Healthy Controls Group Inclusion:
Healthy Controls Group Exclusion:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Shawn Teal | Contact | 507-422-9485 | teal.shawn@mayo.edu | |
| Gregorio Tersalvi, M.D | Contact | tersalvi.gregorio@mayo.edu |
| Name | Affiliation | Role |
|---|---|---|
| Omar Abou Ezzeddine, M.D, M.S | Mayo Clinic | Principal Investigator |
| Gregorio Tersalvi, M.D | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic in Rochester | Recruiting | Rochester | Minnesota | 55905 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C000707753 | 68Ga-FAPI |
Not provided
Not provided
Not provided